Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

It's a good idea to go against the current market sentiment on this one. Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

News headlines Vertex Pharmaceuticals (VRTX) is experiencing notable momentum with revised analyst estimates and a focus on its expanding pipeline. Recent performance has shown a 9.2% increase over ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining traction among investors, buoyed by promising clinical data and potential regulatory advancements. Recent market sentiment also improved due to ...

Kenny Wayne Shepherd is one of the great connoisseurs of electric guitar tone. Over the years he has refined his tastes to ...

What is the Price to Earnings Growth (PEG) Ratio? The PEG Ratio chart for Vertex Pharmaceuticals (VRTX) compares PE to EPS Growth rates. Defining fair value is the goal of measuring valuation using ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 p.m. to 4 a.m. ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...